Improvements in cardiac structure, function seen at 30 weeks of treatment with mavacamten versus placebo.
And LDL cholesterol-lowering therapies are effective for reducing cardiovascular events in older adults
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
BNP or NT-proBNP may represent effective markers for the prediction of contrast-induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.
Risks for first incident CVD increased for higher consumers of sugary drinks, ASBs versus nonconsumers.
In 79% of couples, both members are in nonideal category for cardiovascular health score.
Risk for death, new MI, heart failure lower with metabolic surgery in obese patients with previous MI.
With increasing number of medications, more rapid increase seen in number of noncardiovascular meds.
Incidence of MACE 20.6% within 365 days in patients at increased CV risk.